Your browser doesn't support javascript.
loading
Large-scale cross-sectional seroepidemiologic study of COVID-19 in Japan: Acquisition of herd immunity and the vaccines' efficacy
Zhenxiao Ren; Mitsuhiro Nishimura; Lidya Handayani Tjan; Koichi Furukawa; Yukiya Kurahashi; Silvia Sutandhio; Kaito Aoki; Natsumi Hasegawa; Jun Arii; Kenichi Uto; Keiji Matsui; Itsuko Sato; Jun Saegusa; Nonoka Godai; Kohei Takeshita; Masaki Yamamoto; Tatsuya Nagashima; Yasuko Mori.
Affiliation
  • Zhenxiao Ren; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Mitsuhiro Nishimura; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Lidya Handayani Tjan; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Koichi Furukawa; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Yukiya Kurahashi; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Silvia Sutandhio; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Kaito Aoki; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Natsumi Hasegawa; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Jun Arii; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
  • Kenichi Uto; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan
  • Keiji Matsui; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan
  • Itsuko Sato; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan
  • Jun Saegusa; Department of Clinical Laboratory, Kobe University Hospital, Kobe, Hyogo, Japan
  • Nonoka Godai; Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life Science, University of Hyogo, Hyogo, JapanLife Science Research Infrastructu
  • Kohei Takeshita; Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center, Hyogo, Japan
  • Masaki Yamamoto; Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life Science, University of Hyogo, Hyogo, JapanLife Science Research Infrastructu
  • Tatsuya Nagashima; Hyogo Prefecture Health Promotion Association, Kobe, Hyogo, Japan
  • Yasuko Mori; Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Preprint in English | medRxiv | ID: ppmedrxiv-22269203
ABSTRACT
BackgroundThe COVID-19 pandemic situation has been changing drastically worldwide due to the continuous appearance of SARS-CoV-2 variants and the roll-out of mass vaccination. Periodic cross-sectional studies during the surge of COVID-19 cases is essential to elucidate the pandemic situation. MethodsSera of 1,000 individuals who underwent a health check-up in Hyogo Prefecture Health Promotion Association clinics in Japan were collected in August and December 2021. Antibodies against SARS-CoV-2 N and S antigens were detected in the sera by an electrochemiluminescence immunoassay (ECLIA) and an enzyme-linked immunosorbent assay (ELISA), respectively. The seras neutralization activities for the conventional SARS-CoV-2 (D614G), Delta, and Omicron variants were measured. ResultsThe seropositive rates for the antibody against N antigen were 2.1% and 3.9% in August and December 2021 respectively, demonstrating a Delta variant endemic during that time; the actual infection rate was approximately twofold higher than the rate estimated based on the polymerase chain reaction (PCR)-based diagnosis. The anti-S seropositive rate was 38.7% in August and it reached 90.8% in December, in concordance with the vaccination rate in Japan. In the December cohort, 78.7% of the sera showed neutralizing activity against the Delta variant, whereas that against the Omicron was much lower at 36.6%. ConclusionsThese analyses revealed that herd immunity against SARS-CoV-2 including the Delta variant was established in December 2021, leading to convergence of the variants. The low neutralizing activity against the Omicron variant suggests the need for the further promotion of the prompt three-dose vaccination to overcome this variants imminent 6th wave in Japan. SummarySeroepidemiologic study of COVID-19 on December 2021 in Japan showed neutralizing antibodies for Delta were 78.7%, indicating the acquisition of herd immunity by mass vaccination leading to convergence while those for Omicron were only 36.6%, indicating need of booster vaccination.
License
cc_no
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
Full text: Available Collection: Preprints Database: medRxiv Type of study: Cohort_studies / Observational study / Prognostic study / Rct Language: English Year: 2022 Document type: Preprint
...